Samsung Biologics Co Ltd
KRX:207940
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Samsung Biologics Co Ltd
KRX:207940
|
KR |
|
Archer Materials Ltd
ASX:AXE
|
AU |
|
Amani Gold Ltd
ASX:ANL
|
AU |
|
T
|
TimkenSteel Corp
NYSE:MTUS
|
US |
|
V
|
Valuetronics Holdings Ltd
SGX:BN2
|
HK |
|
TCPL Packaging Ltd
NSE:TCPLPACK
|
IN |
|
N
|
NNIT A/S
CSE:NNIT
|
DK |
|
E
|
Ecomate Holdings Bhd
KLSE:ECOMATE
|
MY |
Wall Street
Price Targets
Price Targets Summary
Samsung Biologics Co Ltd
According to Wall Street analysts, the average 1-year price target for
Samsung Biologics Co Ltd
is 2 266 567.5166 KRW
with a low forecast of 2 018 784.8009 KRW and a high forecast of 2 730 000 KRW.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Samsung Biologics Co Ltd's stock price target?
Price Target
2 266 567.5166
KRW
According to Wall Street analysts, the average 1-year price target for
Samsung Biologics Co Ltd
is 2 266 567.5166 KRW
with a low forecast of 2 018 784.8009 KRW and a high forecast of 2 730 000 KRW.
What is Samsung Biologics Co Ltd's Revenue forecast?
Projected CAGR
16%
For the last 11 years the
compound annual growth rate for
Samsung Biologics Co Ltd's revenue is
41%.
The projected
CAGR
for the next 3 years is
16%.
What is Samsung Biologics Co Ltd's Operating Income forecast?
Projected CAGR
19%
The
compound annual growth rate
of Samsung Biologics Co Ltd's operating income for the next 3 years is
19%.
What is Samsung Biologics Co Ltd's Net Income forecast?
Projected CAGR
16%
The
compound annual growth rate
of Samsung Biologics Co Ltd's net income for the next 3 years is
16%.
